Farallon Capital Management LLC Sells 891,000 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Farallon Capital Management LLC cut its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 99.2% in the third quarter, Holdings Channel reports. The fund owned 7,000 shares of the biopharmaceutical company’s stock after selling 891,000 shares during the quarter. Farallon Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $211,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Fred Alger Management LLC increased its position in Ultragenyx Pharmaceutical by 4.3% during the 3rd quarter. Fred Alger Management LLC now owns 448,717 shares of the biopharmaceutical company’s stock valued at $13,497,000 after purchasing an additional 18,378 shares during the period. Brevan Howard Capital Management LP raised its holdings in shares of Ultragenyx Pharmaceutical by 721.4% in the 3rd quarter. Brevan Howard Capital Management LP now owns 67,035 shares of the biopharmaceutical company’s stock valued at $2,016,000 after purchasing an additional 58,874 shares in the last quarter. Braidwell LP purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $17,708,000. Aquatic Capital Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 79.1% in the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock worth $5,759,000 after purchasing an additional 84,559 shares during the period. Finally, Algert Global LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 176.4% during the third quarter. Algert Global LLC now owns 321,633 shares of the biopharmaceutical company’s stock valued at $9,675,000 after purchasing an additional 205,286 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Phase‑3 win for DTX301 (OTC deficiency): Ultragenyx reported that its AAV8 gene therapy (DTX301) reduced ammonia ~18% versus placebo and maintained normal ammonia through 36 weeks in a late‑stage trial—an important efficacy readout that advances the program toward potential regulatory/commercial milestones. Read More.
• Neutral Sentiment: JPMorgan cuts price target but keeps an Overweight rating: JPMorgan lowered its target from $120 to $74 while maintaining an Overweight stance—reducing near‑term upside expectations but still signaling conviction in the company’s longer‑term potential relative to peers. Read More.
• Negative Sentiment: Multiple securities‑fraud class action notices and lead‑plaintiff deadlines: Several law firms and investor‑alert services (Schall, Robbins Geller, Faruqi, Rosen, Pomerantz, DJS, ClaimsFiler, etc.) have announced a securities class action covering purchases from Aug 3, 2023–Dec 26, 2025 and are soliciting lead‑plaintiff candidates (April 6, 2026 deadline). This increases legal and headline risk, can pressure the stock near term, and may create potential future liabilities. Read More.

Ultragenyx Pharmaceutical Stock Down 1.7%

Shares of Ultragenyx Pharmaceutical stock opened at $21.34 on Monday. The firm has a market capitalization of $2.06 billion, a P/E ratio of -3.65 and a beta of 0.16. The company has a 50 day moving average price of $23.01 and a 200 day moving average price of $28.81. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The company had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. During the same period in the prior year, the firm posted ($1.39) EPS. The firm’s revenue for the quarter was up 25.5% on a year-over-year basis. As a group, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the topic of several research reports. Leerink Partners cut their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Jefferies Financial Group lowered their target price on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. JPMorgan Chase & Co. dropped their target price on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research report on Thursday. Barclays cut their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Finally, Canaccord Genuity Group reduced their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Sixteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $65.76.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 54,404 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at $15,025,063.20. This represents a 7.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Howard Horn sold 1,635 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $22.40, for a total value of $36,624.00. Following the completion of the transaction, the chief financial officer owned 85,034 shares of the company’s stock, valued at $1,904,761.60. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 104,958 shares of company stock valued at $2,394,858. Company insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.